

Astrid Weyerbrock

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1945506/publications.pdf>

Version: 2024-02-01

109
papers

4,614
citations

136950

32
h-index

110387

64
g-index

113
all docs

113
docs citations

113
times ranked

7714
citing authors

#	ARTICLE	IF	CITATIONS
1	External Validation of the Minimum Clinically Important Difference in the Timed-up-and-go Test After Surgery for Lumbar Degenerative Disc Disease. <i>Spine</i> , 2022, 47, 337-342.	2.0	10
2	Distance to first symptoms measured by the 6-min walking test differentiates between treatment success and failure in patients with degenerative lumbar disorders. <i>European Spine Journal</i> , 2022, 31, 596-603.	2.2	2
3	Smartphone-based real-life activity data for physical performance outcome in comparison to conventional subjective and objective outcome measures after degenerative lumbar spine surgery. <i>Brain and Spine</i> , 2022, 2, 100881.	0.1	7
4	Longitudinal neuropsychological assessment after aneurysmal subarachnoid hemorrhage and its relationship with delayed cerebral ischemia: a prospective Swiss multicenter study. <i>Journal of Neurosurgery</i> , 2022, , 1-9.	1.6	3
5	Development of a Complication- and Treatment-Aware Prediction Model for Favorable Functional Outcome in Aneurysmal Subarachnoid Hemorrhage Based on Machine Learning. <i>Neurosurgery</i> , 2021, 88, E150-E157.	1.1	16
6	External Validation of the Timed Up and Go Test as Measure of Objective Functional Impairment in Patients With Lumbar Degenerative Disc Disease. <i>Neurosurgery</i> , 2021, 88, E142-E149.	1.1	5
7	Multifocal lumbar disc herniation at a single level: a potential pitfall for wrong side surgery. <i>British Journal of Neurosurgery</i> , 2021, 35, 120-121.	0.8	0
8	Surgery for IDH1/2 wild-type glioma invading the corpus callosum. <i>Acta Neurochirurgica</i> , 2021, 163, 937-945.	1.7	18
9	Incidence and Outcome of Aneurysmal Subarachnoid Hemorrhage. <i>Stroke</i> , 2021, 52, 344-347.	2.0	49
10	Patients undergoing surgery for lumbar degenerative spinal disorders favor smartphone-based objective self-assessment over paper-based patient-reported outcome measures. <i>Spine Journal</i> , 2021, 21, 610-617.	1.3	15
11	Assessment of the Minimum Clinically Important Difference in the Smartphone-based 6-minute Walking Test After Surgery for Lumbar Degenerative Disc Disease. <i>Spine</i> , 2021, 46, E959-E965.	2.0	5
12	Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 81-99.	1.6	84
13	Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study. <i>Journal of Neuro-Oncology</i> , 2020, 148, 117-130.	2.9	12
14	Longitudinal smartphone-based self-assessment of objective functional impairment in patients undergoing surgery for lumbar degenerative disc disease: initial experience. <i>Acta Neurochirurgica</i> , 2020, 162, 2061-2068.	1.7	9
15	Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. <i>Neuro-Oncology</i> , 2020, 22, 1162-1172.	1.2	42
16	Digital transformation in spine research and outcome assessment. <i>Spine Journal</i> , 2020, 20, 310-311.	1.3	17
17	Evaluation of the 6-minute walking test as a smartphone app-based self-measurement of objective functional impairment in patients with lumbar degenerative disc disease. <i>Journal of Neurosurgery: Spine</i> , 2020, 33, 779-788.	1.7	14
18	Measuring the Impact of Delayed Cerebral Ischemia on Neuropsychological Outcome After Aneurysmal Subarachnoid Hemorrhage—Protocol of a Swiss Nationwide Observational Study (MoCA—DCI Study). <i>Neurosurgery</i> , 2019, 84, 1124-1132.	1.1	11

#	ARTICLE	IF	CITATIONS
19	Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial. <i>Journal of Neuro-Oncology</i> , 2019, 144, 501-509.	2.9	1
20	Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF. <i>Cancer Immunology Research</i> , 2019, 7, 1910-1927.	3.4	74
21	Ruptured posterior circulation aneurysms: epidemiology, patterns of care, and outcomes from the Swiss SOS national registry. <i>Acta Neurochirurgica</i> , 2019, 161, 769-779.	1.7	8
22	Intradural non-calcified thoracic disc herniation causing spontaneous intracranial hypotension: a case report. <i>BMC Surgery</i> , 2019, 19, 66.	1.3	10
23	Conscious Experience and Psychological Consequences of Awake Craniotomy. <i>World Neurosurgery</i> , 2019, 129, e381-e386.	1.3	28
24	Ruptured PICA aneurysms: presentation and treatment outcomes compared to other posterior circulation aneurysms. A Swiss SOS study. <i>Acta Neurochirurgica</i> , 2019, 161, 1325-1334.	1.7	10
25	Cyclooxygenase (COX) Inhibition by Acetyl Salicylic Acid (ASA) Enhances Antitumor Effects of Nitric Oxide in Glioblastoma In Vitro. <i>Molecular Neurobiology</i> , 2019, 56, 6046-6055.	4.0	17
26	Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 678-688.	13.7	384
27	Objective functional assessment using the "Timed Up and Go" test in patients with lumbar spinal stenosis. <i>Neurosurgical Focus</i> , 2019, 46, E4.	2.3	23
28	Patterns of care for ruptured aneurysms of the middle cerebral artery: analysis of a Swiss national database (Swiss SOS). <i>Journal of Neurosurgery</i> , 2019, , 1-10.	1.6	5
29	Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 975-985.	1.2	11
30	Predictors of In-Hospital Death After Aneurysmal Subarachnoid Hemorrhage. <i>Stroke</i> , 2018, 49, 333-340.	2.0	99
31	Predictors of Occurrence and Anatomic Distribution of Multiple Aneurysms in Patients with Aneurysmal Subarachnoid Hemorrhage. <i>World Neurosurgery</i> , 2018, 111, e199-e205.	1.3	14
32	Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). <i>Neuro-Oncology</i> , 2018, 20, 400-410.	1.2	56
33	PATH-42. EGFR-AMPLIFIED IDH-WILDTYPE GLIOBLASTOMAS SELDOM TRANSFORM INTO A HYPERMUTATED PHENOTYPE. <i>Neuro-Oncology</i> , 2018, 20, vi168-vi168.	1.2	0
34	The Barrow Neurological Institute Grading Scale as a Predictor for Delayed Cerebral Ischemia and Outcome After Aneurysmal Subarachnoid Hemorrhage: Data From a Nationwide Patient Registry (Swiss) <i>Tj ETQq0 0.0 rgBT / 39</i>	1.0	10
35	Home-Time as a Surrogate Marker for Functional Outcome After Aneurysmal Subarachnoid Hemorrhage. <i>Stroke</i> , 2018, 49, 3081-3084.	2.0	22
36	Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1581-1589.	2.5	11

#	ARTICLE	IF	CITATIONS
37	Different but similar: personality traits of surgeons and internists” results of a cross-sectional observational study. <i>BMJ Open</i> , 2018, 8, e021310.	1.9	35
38	Whole Transcriptome Screening Reveals Myelination Deficits in Dysplastic Human Temporal Neocortex. <i>Cerebral Cortex</i> , 2017, 27, bhv346.	2.9	16
39	Computed tomography angiography spot sign predicts intraprocedural aneurysm rupture in subarachnoid hemorrhage. <i>Acta Neurochirurgica</i> , 2017, 159, 1305-1312.	1.7	5
40	KLF6 depletion promotes NF- κ B signaling in glioblastoma. <i>Oncogene</i> , 2017, 36, 3562-3575.	5.9	30
41	ATF3 reduces migration capacity by regulation of matrix metalloproteinases via NF- κ B and STAT3 inhibition in glioblastoma. <i>Cell Death Discovery</i> , 2017, 3, 17006.	4.7	26
42	Surgical Treatment of Mesiotemporal Lobe Epilepsy: Which Approach is Favorable?. <i>Neurosurgery</i> , 2017, 81, 992-1004.	1.1	38
43	Epigenetic Regulation of ZBTB18 Promotes Glioblastoma Progression. <i>Molecular Cancer Research</i> , 2017, 15, 998-1011.	3.4	30
44	Integrative Diffusion-Weighted Imaging and Radiogenomic Network Analysis of Glioblastoma multiforme. <i>Scientific Reports</i> , 2017, 7, 43523.	3.3	20
45	Clinical relevance of anterior cerebral artery asymmetry in aneurysmal subarachnoid hemorrhage. <i>Journal of Neurosurgery</i> , 2017, 127, 1070-1076.	1.6	11
46	The nitric oxide donor JS-K sensitizes U87 glioma cells to repetitive irradiation. <i>Tumor Biology</i> , 2017, 39, 101042831770392.	1.8	10
47	Mesoscopic imaging of glioblastomas: Are diffusion, perfusion and spectroscopic measures influenced by the radiogenetic phenotype?. <i>Neuroradiology Journal</i> , 2017, 30, 36-47.	1.2	11
48	Molecular differences between cerebral blood volume and vessel size in glioblastoma multiforme. <i>Oncotarget</i> , 2017, 8, 11083-11093.	1.8	18
49	c-Jun-N-terminal phosphorylation regulates DNMT1 expression and genome wide methylation in gliomas. <i>Oncotarget</i> , 2017, 8, 6940-6954.	1.8	21
50	Comprehensive analysis of PD-L1 expression in glioblastoma multiforme. <i>Oncotarget</i> , 2017, 8, 42214-42225.	1.8	81
51	Intracerebral Hematoma Due to Aneurysm Rupture. <i>Neurosurgery</i> , 2016, 78, 813-820.	1.1	27
52	Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) – protocol of a randomized phase II trial (NOA 10/ARO 2013-1). <i>BMC Cancer</i> , 2016, 16, 769.	2.6	62
53	Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naïve and bevacizumab-resistant glioblastoma. <i>EMBO Molecular Medicine</i> , 2016, 8, 39-57.	6.9	140
54	The predictors and clinical impact of intraventricular hemorrhage in patients with aneurysmal subarachnoid hemorrhage. <i>International Journal of Stroke</i> , 2016, 11, 68-76.	5.9	28

#	ARTICLE	IF	CITATIONS
55	Phase II Study of Radiotherapy and Temozolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without <i>O⁶-MGMT</i> Promoter Hypermethylation (EORTC 26082). <i>Clinical Cancer Research</i> , 2016, 22, 4797-4806.	7.0	105
56	Nitric oxide released from JS-K induces cell death by mitotic catastrophe as part of necrosis in glioblastoma multiforme. <i>Cell Death and Disease</i> , 2016, 7, e2349-e2349.	6.3	16
57	Integrative Modeling Reveals Annexin A2-mediated Epigenetic Control of Mesenchymal Glioblastoma. <i>EBioMedicine</i> , 2016, 12, 72-85.	6.1	21
58	Integrative Network-based Analysis of Magnetic Resonance Spectroscopy and Genome Wide Expression in Glioblastoma multiforme. <i>Scientific Reports</i> , 2016, 6, 29052.	3.3	19
59	Residual Tumor Volume as Best Outcome Predictor in Low Grade Glioma – A Nine-Years Near-Randomized Survey of Surgery vs. Biopsy. <i>Scientific Reports</i> , 2016, 6, 32286.	3.3	110
60	Glioma vessel abnormality quantification using time-of-flight MR angiography. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2016, 29, 765-775.	2.0	4
61	Stereotactic fractionated radiotherapy of the resection cavity in patients with one to three brain metastases. <i>Clinical Neurology and Neurosurgery</i> , 2016, 142, 81-86.	1.4	21
62	Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed <i>O⁶-Methylguanine</i> -DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1611-1619.	1.6	151
63	Malignant Transformation of a Dysembryoplastic Neuroepithelial Tumor (DNET) Characterized by Genome-Wide Methylation Analysis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 358-365.	1.7	27
64	Early Vasospasm after Aneurysmal Subarachnoid Hemorrhage Predicts the Occurrence and Severity of Symptomatic Vasospasm and Delayed Cerebral Ischemia. <i>Cerebrovascular Diseases</i> , 2016, 41, 265-272.	1.7	26
65	Decrease of VEGF-A in myeloid cells attenuates glioma progression and prolongs survival in an experimental glioma model. <i>Neuro-Oncology</i> , 2016, 18, 939-949.	1.2	38
66	Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine. <i>Journal of Neuro-Oncology</i> , 2016, 126, 567-575.	2.9	31
67	Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection. <i>Neuro-Oncology</i> , 2016, 18, 96-104.	1.2	186
68	Surgical Ventricular Entry is a Key Risk Factor for Leptomeningeal Metastasis of High Grade Gliomas. <i>Scientific Reports</i> , 2015, 5, 17758.	3.3	31
69	Freiburg Neuropathology Case Conference. A Mass Lesion of the Fourth Ventricle. <i>Clinical Neuroradiology</i> , 2015, 25, 439-443.	1.9	2
70	Whole brain irradiation with hippocampal sparing and dose escalation on multiple brain metastases. <i>Strahlentherapie Und Onkologie</i> , 2015, 191, 461-469.	2.0	77
71	Early Identification of Individuals at High Risk for Cerebral Infarction after Aneurysmal Subarachnoid Hemorrhage: The BEHAVIOR Score. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 1587-1592.	4.3	40
72	Lack of evidence for PlGF mediating the tumor resistance after anti-angiogenic therapy in malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2015, 121, 269-278.	2.9	7

#	ARTICLE	IF	CITATIONS
73	Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas. <i>Acta Neuropathologica</i> , 2015, 129, 115-131.	7.7	122
74	<i>TERT</i> promoter mutations and telomere length in adult malignant gliomas and recurrences. <i>Oncotarget</i> , 2015, 6, 10617-10633.	1.8	79
75	Outcome Prediction after Non-aneurysmal Non-traumatic Subarachnoid Hemorrhage. <i>Current Neurovascular Research</i> , 2015, 12, 269-276.	1.1	7
76	Simultaneous assessment of vessel size index, relative blood volume, and vessel permeability in a mouse brain tumor model using a combined spin echo gradient echo echo-planar imaging sequence and viable tumor analysis. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 40, 1310-1318.	3.4	15
77	Freiburg Neuropathology Case Conference: Multiple Small Ring-Enhancing Lesions in a 75-Year-Old Patient. <i>Clinical Neuroradiology</i> , 2014, 24, 193-197.	1.9	0
78	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1100-1108.	10.7	800
79	Freiburg Neuropathology Case Conference: Tumor of the Cerebellum with Mild, Gyriiform Enhancement in a 19-Year-Old Patient. <i>Clinical Neuroradiology</i> , 2014, 24, 301-306.	1.9	0
80	Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression. <i>Journal of Clinical Investigation</i> , 2014, 124, 2861-2876.	8.2	83
81	Global Tracking in Human Gliomas: A Comparison with Established Tracking Methods. <i>Clinical Neuroradiology</i> , 2013, 23, 263-275.	1.9	7
82	Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI. <i>Nitric Oxide - Biology and Chemistry</i> , 2013, 30, 17-25.	2.7	18
83	JS-K, a Glutathione S-Transferase-Activated Nitric Oxide Donor With Antineoplastic Activity in Malignant Gliomas. <i>Neurosurgery</i> , 2012, 70, 497-510.	1.1	42
84	Freiburg Neuropathology Case Conference: Widespread Mass Lesions After Resection of a Glioblastoma Multiforme. <i>Clinical Neuroradiology</i> , 2012, 22, 375-380.	1.9	1
85	Chloroquine or Chloroquine-PI3K/Akt Pathway Inhibitor Combinations Strongly Promote $\hat{\gamma}$ -Irradiation-Induced Cell Death in Primary Stem-Like Glioma Cells. <i>PLoS ONE</i> , 2012, 7, e47357.	2.5	86
86	Growth-inhibitory and chemosensitizing effects of the glutathione S-transferase-activated nitric oxide donor PABA/NO in malignant gliomas. <i>International Journal of Cancer</i> , 2012, 130, 1184-1194.	5.1	44
87	Freiburg Neuropathology Case Conference. <i>Clinical Neuroradiology</i> , 2011, 21, 35-39.	1.9	0
88	Delayed cell death associated with mitotic catastrophe in $\hat{\gamma}$ -irradiated stem-like glioma cells. <i>Radiation Oncology</i> , 2011, 6, 71.	2.7	34
89	<i>NFKBIA</i> Deletion in Glioblastomas. <i>New England Journal of Medicine</i> , 2011, 364, 627-637.	27.0	220
90	Differential effects of nitric oxide on blood-brain barrier integrity and cerebral blood flow in intracerebral C6 gliomas. <i>Neuro-Oncology</i> , 2011, 13, 203-211.	1.2	33

#	ARTICLE	IF	CITATIONS
91	Freiburg Neuropathology Case Conference: a Diffusely Infiltrating Lesion. <i>Clinical Neuroradiology</i> , 2010, 20, 70-73.	1.9	0
92	Outcome correlates with blood distribution in subarachnoid hemorrhage of unknown origin. <i>Acta Neurochirurgica</i> , 2010, 152, 417-422.	1.7	16
93	Reactive oxygen species (ROS) in the human neocortex: Role of aging and cognition. <i>Brain Research Bulletin</i> , 2010, 81, 484-490.	3.0	34
94	Growth inhibition and chemosensitization of exogenous nitric oxide released from NONOates in glioma cells in vitro. <i>Journal of Neurosurgery</i> , 2009, 110, 128-136.	1.6	31
95	Aneurysmal and Non-Aneurysmal SAH – Is Initial Computed Tomography Predictive?. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2009, 181, 881-887.	1.3	6
96	Gravitational valves in supine patients with ventriculo-peritoneal shunts. <i>Acta Neurochirurgica</i> , 2009, 151, 705-709.	1.7	10
97	Effects of gabapentin and pregabalin on K ⁺ -evoked 3H-GABA and 3H-glutamate release from human neocortical synaptosomes. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2009, 379, 361-369.	3.0	27
98	Differential inhibitory effects of drugs acting at the noradrenaline and 5-HT _{2A} hydroxytryptamine transporters in rat and human neocortical synaptosomes*. <i>British Journal of Pharmacology</i> , 2009, 158, 1848-1856.	5.4	17
99	Differential modulation of K ⁺ -evoked 3H-neurotransmitter release from human neocortex by gabapentin and pregabalin. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2008, 376, 301-307.	3.0	30
100	Endoscopic Fenestration of A Symptomatic Cavum Septum Pellucidum: Technical Case Report. <i>Operative Neurosurgery</i> , 2006, 59, ONS-E491-ONS-E491.	0.8	13
101	Interdisciplinary Pain Therapy: An Innovative Therapeutic but Pre-DRG Economical Center of Medical Excellence. <i>Zentralblatt Fur Neurochirurgie</i> , 2006, 67, 67-75.	0.5	1
102	Gliomas: quo vadis. <i>Clinical Neurosurgery</i> , 2006, 53, 58-63.	0.2	6
103	Early-stage penile carcinoma metastasizing to brain: Case report and literature review. <i>Urology</i> , 2005, 66, 432.e9-432.e11.	1.0	7
104	Selective opening of the blood-brain barrier by a nitric oxide donor and long-term survival in rats with C6 gliomas. <i>Journal of Neurosurgery</i> , 2003, 99, 728-737.	1.6	45
105	Gene transfer technologies for malignant gliomas. <i>Current Opinion in Oncology</i> , 1999, 11, 168.	2.4	21
106	Improving Drug Delivery to Intracerebral Tumor and Surrounding Brain in a Rodent Model: A Comparison of Osmotic versus Bradykinin Modification of the Blood-Brain and/or Blood-Tumor Barriers. <i>Neurosurgery</i> , 1998, 43, 886-887.	1.1	14
107	Effect of LINAC Radiosurgery on Regional Cerebral Blood Flow, Glucose Metabolism and Sodium-Potassium ATPase in Skull Base Meningiomas and Metastasis. <i>Acta Neurochirurgica Supplementum</i> , 1997, 68, 124-126.	1.0	6
108	Effects of light and chronotherapy on human circadian rhythms in delayed sleep phase syndrome: Cytokines, cortisol, growth hormone, and the sleep-wake cycle. <i>Biological Psychiatry</i> , 1996, 40, 794-797.	1.3	33

#	ARTICLE	IF	CITATIONS
109	Cytokine Production during Sleep and Wakefulness and Its Relationship to Cortisol in Healthy Humans. <i>Neuropsychobiology</i> , 1993, 28, 9-16.	1.9	53